

The Manager
Company Announcements
Australian Securities Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

16 February 2009

Resonance Health announces Board Appointment of Stewart Washer (BSc, PhD)


Resonance Health is pleased to announce the appointment of Dr Stewart Washer to the Board as non-executive director and Chairman of the Board, effective immediately. Stewart has over 20 years experience in life science companies, as CEO, Founder and Director.

Dr Washer was the founding CEO of Phylogica Ltd and left at the end of 2007 to pursue fund management and Directorships. Prior to this Dr Washer managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and \$130m revenues as Cellentis CEO. Dr Washer has raised seed capital and significant shareholder and government funds in various businesses, and completed a number of profitable trade sales. He founded and raised a NZ\$120m life science fund, BioPacific Ventures.

Dr Washer's current directorships include Genesis R&D Ltd, Healthlinx Ltd, AusBiotech Ltd and Hatchtech Pty Ltd and he is a Senator of Murdoch University and a Venture Partner with the Swiss Inventages Fund, a €1.5 billion life science fund and the Investment Consultant with the IB Bioscience Funds.

Resonance Health is delighted Dr Washer has joined the board as we move forward with expansion into the broader international market. Dr Washer joins the board at a time when the Company is on a sound financial footing with profitable earnings and \$2.75m cash in the bank. Sales of FerriScan[®] over the first 6 months of this financial year have resulted in over \$1m of revenue, up 16% over the previous year. Activities during this period have focused on increasing FerriScan[®] sales, achieving reimbursement for FerriScan[®] and research and development on FibroScreen[™], an MRI test for liver fibrosis. These activities include:

- Commencement of a clinical study to review the role of FerriScan[®] in providing an accurate iron measurement for patients waiting for a liver transplant.
- Commencement of a clinical study to validate product improvements aimed at reducing the MRI scan time for a FerriScan[®] from 20-25 minutes to 10-12 minutes, improving the financial competitiveness of FerriScan[®].
- Commencement of a clinical study to further develop FibroScreen[™] for the scoring of liver fibrosis, a problem affecting patients with a chronic liver disease such as Hepatitis C, which affects over 2.7m patients in the US alone.
- Formalisation of Resonance Health's presence in the UK with a UK based Marketing Representative.
- Campaigning to expand the initial reimbursement success of FerriScan[®].



Resonance Health welcomes Dr Washer to the company's Board of Directors, at this exciting time in its expansion.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@ferriscan.com

Eva O'Malley
Company Secretary
T: +61 8 9286 5300
E: evao@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing core laboratory services utilising advanced medical technology for the analysis of medical images. It's patented technology FerriScan[®], provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. Initial commercialisation of FerriScan[®] has focused on pharmaceutical companies developing drug therapies to treat iron overload, and is now being extended to the broader international clinical community.